Kidney Damage in Patients With Moderate Fall in eGFR
Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320
Sponsor: Bracco Diagnostics, Inc
Listed as NCT01136876, this PHASE4 trial focuses on Coronary Artery Stenosis and remains completed. Sponsored by Bracco Diagnostics, Inc, it has been updated 9 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Oct 2020 — Dec 2020 [monthly]
Completed PHASE4
-
Jun 2018 — Oct 2020 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bracco Diagnostics, Inc
For direct contact, visit the study record on ClinicalTrials.gov .